These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 6487440

  • 1. Investigation of malignant hyperthermia in Denmark and Sweden.
    Ording H, Ranklev E, Fletcher R.
    Br J Anaesth; 1984 Nov; 56(11):1183-90. PubMed ID: 6487440
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
    Br J Anaesth; 1984 Nov; 56(11):1267-9. PubMed ID: 6487446
    [Abstract] [Full Text] [Related]

  • 4. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H, Bendixen D.
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [Abstract] [Full Text] [Related]

  • 5. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels.
    Weglinski MR, Wedel DJ, Engel AG.
    Anesth Analg; 1997 May; 84(5):1038-41. PubMed ID: 9141928
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Static v. dynamic tests in the in vitro diagnosis of malignant hyperthermia susceptibility.
    Ranklev E, Fletcher R, Blomquist S.
    Br J Anaesth; 1986 Jun; 58(6):646-8. PubMed ID: 3707802
    [Abstract] [Full Text] [Related]

  • 9. [Diagnosis of susceptibility to malignant hyperthermia in children].
    Krivosic-Horber R, Adnet P, Krivosic I, Reyford H.
    Arch Fr Pediatr; 1990 Jun; 47(6):421-4. PubMed ID: 2403268
    [Abstract] [Full Text] [Related]

  • 10. Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia?
    Ellis FR, Halsall PJ, Hopkins PM.
    Br J Anaesth; 1992 Nov; 69(5):468-70. PubMed ID: 1467078
    [Abstract] [Full Text] [Related]

  • 11. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
    Sudo RT, Cunha LB, Carmo PL, Matos AR, Trachez MM, Cardoso LA, Aguiar MI, Abreu AV, Zapata-Sudo G.
    Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Propofol is a 'safe' anaesthetic agent in malignant hyperthermia susceptible patients.
    McKenzie AJ, Couchman KG, Pollock N.
    Anaesth Intensive Care; 1992 May; 20(2):165-8. PubMed ID: 1595850
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
    Urwyler A, Censier K, Kaufmann MA, Drewe J.
    Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
    [Abstract] [Full Text] [Related]

  • 18. In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium and caffeine-suxamethonium.
    Ording H, Skovgaard LT.
    Acta Anaesthesiol Scand; 1987 Jul; 31(5):462-5. PubMed ID: 3630591
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.